R

Regenlab USA Inc.

RGNAFiled

Regenlab USA Inc. · Nasdaq · latest filing 2026-09-25

Report source
One-minute decisionBASIC RESEARCHSource completeness · 67%

Preliminary S-1 leaves core IPO terms incomplete despite established regenerative-medicine operations.

As of the September 25, 2026 S-1, RegenLab’s IPO price, share count and proceeds remain placeholders, while Nasdaq listing is unapproved.

Where does the money go?Awaiting verificationS-1 · 2026-09-25
Ownership and votingAntonino Turzi98.64% economic · Awaiting verification voting
Next disclosed checkpointSEC effectiveness and completion of final offering terms; no confirmed closing or trading date is supplied.S-1 · 2026-09-25

Capital destination

Awaiting verification

S-1 · 2026-09-25

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · S-1 ↗
Next checkSEC effectiveness and completion of final offering terms; no confirmed closing or trading date is supplied.
Latest filing2026-09-25

Capital destination

Awaiting verification

S-1 · 2026-09-25

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · S-1 ↗
BOOKRUNNERS / LEAD UNDERWRITERSBookrunners / lead underwriters
NOT YET DISCLOSED

Names not yet published

Fully diluted valuation bridge

StatusReference
Awaiting verificationSource ↗

Basic-price scenario

A verified single offer price and basic post-offer share count are required. This is a data gap, not a paid lock.

Check the source · S-1 ↗

Antonino Turzi

98.64%

beneficial ownership before offering

Antonino Turzi remains the dominant holder and voting controller; post-offering percentages are blank. · 2026-09-25

Antonino Turzi remains the dominant holder and voting controller; post-offering percentages are blank.

One disclosed holder; not a complete ownership distribution.Check the source · S-1 ↗

Conditional lock-up timeline

StatusReference
Awaiting verificationSource ↗

Financial quality and runway

StatusReference
Awaiting verificationSource ↗

Latest filing update

Loading saved filing update…

SEC filing history

Loading filing history…

Risk 1

Failure to obtain or maintain CE-MDR, FDA 510(k), PMA or other approvals could delay or prevent commercialization.

Potential impact
Awaiting verification
Monitor
SEC effectiveness and completion of final offering terms; no confirmed closing or trading date is supplied.
SEC EDGAR

S-1

2026-09-25

Open SEC filing ↗